INTRODUCTION AND OBJECTIVES: Current treatments for cystinuria have limited effectiveness as well as short and long-term side effects. Dilutional therapy reduces recurrence, but many patients have difficulty maintaining high fluid intake. The vasopressin V2-receptor antagonist tolvaptan increases urinary excretion of free water. We sought to perform a pilot study of short-term safety, tolerability, and impact of oral tolvaptan on urinary stone risk parameters. METHODS: We enrolled cystinuria patients age 12-25 yrs. Subjects were treated for 4 days at lower dose (0.3 mg/kg daily, up to 30 mg) and 4 days at higher dose (0.6 mg/kg daily, up to 60 mg). Subjects were closely monitored throughout the study period. 24 hour urine collections were done at baseline, at day 3-4 of the dosing period, at day 7-8 of the dosing period, and 3-6 days after washout. Primary outcome was cystine capacity (mg/L), a measure of supersaturation unaffected by concurrent treatment with sulfhydryl drugs. Target capacity is a positive value. Secondary outcomes included other urinary/ serum parameters, tolerability, and thirst response. Subjects continued their home medical regimen (including tiopronin) during the study period.
INTRODUCTION AND OBJECTIVES: Current treatments for cystinuria have limited effectiveness as well as short and long-term side effects. Dilutional therapy reduces recurrence, but many patients have difficulty maintaining high fluid intake. The vasopressin V2-receptor antagonist tolvaptan increases urinary excretion of free water. We sought to perform a pilot study of short-term safety, tolerability, and impact of oral tolvaptan on urinary stone risk parameters.
METHODS: We enrolled cystinuria patients age 12-25 yrs. Subjects were treated for 4 days at lower dose (0.3 mg/kg daily, up to 30 mg) and 4 days at higher dose (0.6 mg/kg daily, up to 60 mg). Subjects were closely monitored throughout the study period. 24 hour urine collections were done at baseline, at day 3-4 of the dosing period, at day 7-8 of the dosing period, and 3-6 days after washout. Primary outcome was cystine capacity (mg/L), a measure of supersaturation unaffected by concurrent treatment with sulfhydryl drugs. Target capacity is a positive value. Secondary outcomes included other urinary/ serum parameters, tolerability, and thirst response. Subjects continued their home medical regimen (including tiopronin) during the study period.
RESULTS: 2 females (17, 23 yrs) and 2 males (13, 24 yrs) were enrolled. Cystine capacity respectively went from baseline of -312, -82, -353 and -628 mg/L to 97, 111, 75 and -3 mg/L on high dose (Figure 1 ). 24-hour volume went from 1.96, 3.0, 2.1 and 0.91 L to 11.74, 6.5, 9.9 and 2.8 L on high dose (Figure 2 ). There were no abnormalities in serum electrolytes or liver enzymes during the treatment period. Subjects did experience severe thirst, with thirst rated 9/10 on a visual analog scale, but all completed treatment and none terminated or reduced dose.
CONCLUSIONS: Dilutional therapy with tolvaptan increased both cystine capacity and urinary volumes. This treatment approach has the potential to reduce recurrence of stones in this population. Further investigation should study longer term effects and safety, and determine optimal dosing to improve tolerability.
Source of Funding:
Otsuka Pharmaceuticals provided the study drug at no cost. The authors otherwise have no financial or other interest in Otsuka or in the study medication.
MP12-05 UTILIZATION OF A SMART WATER BOTTLE TO INCREASE FLUID INTAKE IN STONE FORMERS
Thomas Stout*, Minneapolis, MN; James Lingeman, Amy Krambeck, Indianapolis, IN; Mitchell Humphreys, Scottsdale, AZ; Anna Zisman, Chicago, IL; Sarah Elfering, Michael Borofsky, Minneapolis, MN INTRODUCTION AND OBJECTIVES: High dietary fluid intake is a cornerstone of kidney stone prevention; yet, is challenging to achieve. There is interest in using smart water bottles for this purpose but sparse data exists as to whether such technology leads to better outcomes relative to standard counseling. We sought to assess whether the addition of a smart water bottle to standard dietary fluid recommendations leads to improved urine volume.
METHODS: IRB approval was obtained to offer voluntary enrollment into a prospective randomized controlled trial comparing the effect of standard dietary fluid recommendations (DR) to standard DR with addition of a smart water bottle (SB) on 24 hour urine (24 hr U) volume. Eligible participants included those over age 18 with a history of nephrolithiasis and low urine volume (<1.5L) in the past 6 months. All subjects received a handout with strategies to achieve a goal urine output of 2.5 L/day. The intervention arm also received a smart water bottle (HidrateSpark, Minneapolis MN) with a sensor that recorded daily fluid intake, synced to the user's smartphone, and provided periodic reminders to drink. All patients completed a baseline survey to assess Vol. 201, No. 4S, Supplement, Friday, May 3, 2019 THE JOURNAL OF UROLOGY Ò e169 barriers to achieving adequate fluid intake. They then repeated a 24hr U at 6 weeks and a repeat survey at 12 weeks. RESULTS: 77 subjects (38 DR, 39 SB) have been enrolled to date. Baseline demographics between groups are similar (table 1) . Among all participants at baseline, the main reported factor limiting sufficient fluid intake is not remembering to drink (58%). 62% report being very motivated to increase fluid intake. Follow up 24Hr U are available for 42 patients (23 DR, 19 SB). Both groups have shown increases in 24 hr U volume with mean increase being greater in the SB cohort (1.3L vs 0.8L). Among follow up survey respondents, both cohorts report subjective increases in fluid intake (cups/day) (0.75 SB vs 1.11 DR). Fewer patients in the SB arm report not remembering to drink as the main factor limiting sufficient fluid intake compared to the DR arm (38 vs. 76%).
CONCLUSIONS: Difficulty remembering to drink is a common barrier in achieving sufficient fluid intake for stone formers. Addition of a smart bottle to dietary recommendations may lead to greater increases in 24 Hr U volumes and less difficulty remembering to drink.
Source of Funding: HidrateSpark

MP12-06 REDUCING OPIATE USE IN EMERGENCY DEPARTMENT MANAGEMENT OF ACUTE RENAL COLIC
Andrew Portis*, St. Paul, MN; Michael Borofsky, Minneapolis, MN; Suzanne Neises, St Paul, MN INTRODUCTION AND OBJECTIVES: Opiate dependence is an important issue for urolithiasis patients that often begins in the emergency department (ED) when presenting with renal colic. Herein, we report on impact of an initiative to increase non-opiate ED management of renal colic.
METHODS: ED physicians (n[57) in 3 EDs within a US metropolitan health system received structured education on the efficacy of acetaminophen and ketorolac in the management of renal colic institution specific data. They were encouraged to consider initiating care with oral acetaminophen and/or IV ketorolac rather than opiates. Treatment patterns were observed in patients presenting with CT confirmed, unilateral ureteral stones (2-10 mm), initial pain scores !6/10, and creatinine clearance >30 ml/min/1.73m 2 . Patients were categorized by initial medical strategy with medications administered within 10 minutes of each other considered as elements of a single strategy. Primary outcome metric was overall opiate use.
RESULTS: Patient and stone characteristics were similar between both periods. (Table 1 ) Following introduction of the initiative there was an increase in using non-narcotic agents as first line therapy (36% to 51%, P<0.001). Administration of secondary analgesics remained stable over time but use of secondary opioids declined. Use of ondansetron declined while ED length of stay and hospital admission rate remained stable. Overall use of ketorolac remained stable while acetaminophen use increased and opiate use declined. (Figure 1 ) Across phases, patients with highest initial pain score (10/10) were more likely to receive opioids (odds ratio (OR) 6.4, 95% confidence interval (CI) 3. 16-12.98, p<0.001 Opioid analgesics are often employed in the management of acute renal colic. However, prescription (Rx) opioids are recognized as the leading initial exposure for those suffering from chronic opioid use and abuse. We sought to describe the cohort of stone formers who, after an initial opioid Rx, subsequently received repeated opioid prescriptions. Additionally, we sought to determine the frequency of prolonged opioid use greater than 1 year after the index stone diagnosis and assess predictors for this prolonged opioid use.
METHODS: We assessed the cohort of US adults participating in the Medical Expenditure Panel Survey between 2005 and 2015. This nationally-representative survey collects longitudinal data regarding medical diagnoses, encounters, and prescription drug use. Each participant is surveyed every 6 months over the course of 2 years.
